Document is current
Any future updates will be listed below
-
Authors
Goldsmith, Kelly C.
Park, Julie R.
Kayser, Kimberly
Malvar, Jemily
Chi, Yueh-Yun
Groshen, Susan G.
Villablanca, Judith G.
Krytska, Kateryna
Lai, Lillian M.
Acharya, Patricia T.
Goodarzian, Fariba
Pawel, Bruce
Shimada, Hiroyuki
Ghazarian, Susan
States, Lisa
Marshall, Lynley
Chesler, Louis https://orcid.org/0000-0001-7842-2068
Granger, Meaghan
Desai, Ami V.
Mody, Rajen
Morgenstern, Daniel A. https://orcid.org/0000-0002-4859-1108
Shusterman, Suzanne
Macy, Margaret E. https://orcid.org/0000-0001-6446-9180
Pinto, Navin https://orcid.org/0000-0002-8775-6710
Schleiermacher, Gudrun https://orcid.org/0000-0002-0133-5879
Vo, Kieuhoa
Thurm, Holger C.
Chen, Joseph https://orcid.org/0000-0002-5998-7765
Liyanage, Marlon
Peltz, Gerson
Matthay, Katherine K.
Berko, Esther R.
Maris, John M. https://orcid.org/0000-0002-8088-7929
Marachelian, Araz
Mossé, Yael P. https://orcid.org/0000-0002-3463-0399
- License Information
-
More Information
Article History
Received: 26 October 2022
Accepted: 9 March 2023
First Online: 3 April 2023
Competing interests
: The authors declare the following competing interests. Y.P.M. is the principal investigator of the NANT phase 1 trial of lorlatinib and is a consultant for Pfizer. Y.P.M. has previously received research funding from Pfizer and Novartis. Y.P.M. has also served as a consultant for Lilly, Auron Therapeutics and Jumo Health. Y.P.M. serves as a member of the Data and Safety Monitoring Committee for the ASCO TAPUR study and receives honoraria for this role. H.T. is an employee of Pfizer and holds Pfizer stock. J.S. was an employee of Pfizer during the conduct and analysis of this work, currently owns Pfizer stock and is currently employed by Roche-Genentech. M.L. is a postdoctoral fellow with funding supported by Pfizer. G.P., at the time of study, was employed by Pfizer and held company stock. A.M. and NANT clinical research operations received funding from Pfizer in support of this study. K.C.G. has been an uncompensated consultant to Y-mAbs Therapeutics. L.M. has been a consultant or advisor for Bayer, Bristol Myers Squibb, Illumina and Tesaro and served as an EDMC member on studies run by Eisai and Merck. A.D. has stock ownership in Pfizer and Viatris and has acted as a paid consultant or advisor for Merck, Ology Medical Education, Y-mAbs Therapeutics and GlaxoSmithKline. D.A.M. has been a consultant or advisory board member to Y-mAbs Therapeutics, Clarity Pharmaceuticals, RayzeBio and Oncoheroes Biosciences. G.S. has received research funding from Bristol Myers Squibb, MSDavenir, Roche and Pfizer for research projects distinct from this trial. K.M. is a consultant with Y-mabs Therapeutics and RayzeBio. R.M. is on the Data and Safety Monitoring Committee for Y-Mabs Therapeutics and Jubilant Draximage. M.M. has stock in Johnson & Johnson, GE Healthcare and Varian Medical Systems. M.M. has been a consultant or advisory board memebr to Y-mAbs Therapeutics and has received research funding from Bayer, Ignyta, Roche, Lilly, Merck, Oncternal Therapeutics, AbbVie, Jubilant Draxlmage and Actuate Therapeutics. The remaining authors declare no competing interests.
